Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations

View ORCID ProfileMarilyne Labrie, Allen Li, Allison Creason, Courtney Betts, Jamie Keck, Brett Johnson, Shamilene Sivagnanam, Christopher Boniface, Hongli Ma, Aurora Blucher, Young Hwan Chang, Koei Chin, Jacqueline Vuky, Alexander R. Guimaraes, Molly Downey, Jeong Youn Lim, Lina Gao, Kiara Siex, Swapnil Parmar, Annette Kolodzie, Paul T Spellman, Jeremy Goecks, Lisa M. Coussens, Christopher L. Corless, Raymond Bergan, Joe W. Gray, Gordon B. Mills, Zahi I. Mitri
doi: https://doi.org/10.1101/2020.07.25.20146431
Marilyne Labrie
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
2Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marilyne Labrie
  • For correspondence: mitri@ohsu.edu labriem@ohsu.edu
Allen Li
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison Creason
3Computational Biology Program, Oregon Health and Science University, Portland, OR, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Courtney Betts
2Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie Keck
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
6Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett Johnson
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
6Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, United States
7Department of Biomedical Engineering, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shamilene Sivagnanam
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
3Computational Biology Program, Oregon Health and Science University, Portland, OR, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Boniface
4Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongli Ma
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
2Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurora Blucher
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
2Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young Hwan Chang
3Computational Biology Program, Oregon Health and Science University, Portland, OR, United States
6Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, United States
7Department of Biomedical Engineering, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koei Chin
6Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, United States
7Department of Biomedical Engineering, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline Vuky
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander R. Guimaraes
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
5Department of Diagnostic Radiology, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Molly Downey
5Department of Diagnostic Radiology, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeong Youn Lim
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lina Gao
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kiara Siex
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Swapnil Parmar
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette Kolodzie
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
6Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul T Spellman
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
4Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, United States
6Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Goecks
3Computational Biology Program, Oregon Health and Science University, Portland, OR, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa M. Coussens
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
2Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher L. Corless
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
8Department of Pathology, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond Bergan
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe W. Gray
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
6Center for Spatial Systems Biomedicine (OCSSB), Oregon Health and Science University, Portland, United States
7Department of Biomedical Engineering, Oregon Health and Science University, Portland, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon B. Mills
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
2Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, United States
9Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zahi I. Mitri
1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mitri@ohsu.edu labriem@ohsu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Due to complexity of advanced epithelial cancers, it is necessary to implement patient specific combination therapies if we are to markedly improve patient outcomes. However, our ability to select and implement patient specific combination therapies based on dynamic molecular changes in the tumor and tumor ecosystem in response to therapy remains extremely limited. In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). Although PARP inhibition was consistently observed in all patients, deep molecular analysis of the tumor and its ecosystem revealed insights into potentially effective therapeutic PARPi combinations. In a BRCA-mutant basal breast cancer exceptional long-term survivor, we noted striking PARPi-induced tumor destruction accompanied by a marked infiltration of immune cells containing CD8 effector cells, consistent with pre-clinical evidence for association between STING mediated immune activation and benefit from PARPi and immunotherapy. Tumor cells in the exceptional responder underwent extensive protein network rewiring in response to PARP inhibition. In contrast, there were minimal changes in the ecosystem of a luminal androgen receptor (LAR) rapid progressor in response to PARPi likely due to indifference to the effects of PARP inhibition. In this rapid progressor, there was minimal evidence of immune activation or protein network rewiring in response to PARPi, despite PARP being inhibited, and no clinical benefit was noted for this participant. Together, deep real-time analysis of longitudinal biopsies identified a suite of PARPi-induced emergent changes including immune activation, DNA damage checkpoint activation, apoptosis and signaling pathways including RTK, PI3K-AKT and RAS-MAPK, that could be used to select patient specific combination therapies, based on tumor and immune state changes that are likely to benefit specific patients.

Highlights

  • Longitudinal analysis of serial tumor samples in real-time identifies adaptive mechanisms of resistance to PARPi therapies.

  • Deep molecular analysis of the tumor reveals insights into potentially effective therapeutic PARPi combinations.

  • Extensive protein network rewiring, microenvironment and immune state changes are assessable factors for patient specific combination therapies.

Competing Interest Statement

GBM: Consultant/Scientific Advisory Board (AstraZeneca, Chrysalis, ImmunoMET, Ionis, Lilly USA, LLC, PDX Pharma, Signalchem Lifesciences, Symphogen, Tarveda); Stock/Options/Financial Companies (Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Ventures, Tarveda); Licensed Technology Companies (HRD assay to Myriad Genetics, DSP to Nanostring); CLC: Consultant/Scientific Advisory Board (Amgen, Cepheid/Daneher); Stock/Options (Guardant Health); RB: inventor on patents related to KBU2046 and therapeutically targeting cancer motility, and co-owner of Third Coast Therapeutics, which has an option to license those patents; JV: Consultant/Scientific Advisory Board (Seattle Genetics/Astellas), research funding (Celldex, Innocrin Pharma, Roche/Genentech, Novartis, Merck, Fortis Therapeutics). LMC: paid consultant for Cell Signaling Technologies, received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., and NanoString Technologies, and is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc, Verseau Therapeutics, Kineta, Inc., and Cytomix Therapeutics, Inc. ARG: Siemens Speaker's Bureau, Consultant for Takeda Pharmaceuticals, Inc., Expert Witness for Rice, Dolan & Kershaw and Witherspoon & Kelley. PTS: IP licensed to Cepheid, equity in convergent genomics, consulting for Foundation Medicine. JGW: Business Relationships (Abbott Diagnostics, Danaher (formerly Cepheid), PDX Pharmaceuticals and Thermo Fisher Scientific (formerly FEI), Zeiss, Micron), Company Ownership Positions (Convergent Genomics, KromaTid, PDX Pharmaceuticals), Full- or Part-time Employment or Service as an Officer, Board Member or Other Position of Leadership (Oregon Health & Science University; Cooperative Japan-United States Radiation Effects Research Foundation), Consulting or Advisory Relationships (APOBEC Cancer Program, University of Minnesota; Comprehensive Cancer Center, University of New Mexico (UNM); MJ Murdock Charitable Trust; New Leaf Ventures; Susan G. Komen for the Cure, University of Denver Medical Center), Stock Ownership (Abbott Diagnostics, AbbVie, Alphabet, Amgen, Amazon, Apple Corporation, Berkshire Hathaway, Cameco, Chevron, ConocoPhillips, Cisco Systems, Clorox, Colgate-Palmolive, Crown Castle, Devon Energy, Disney, Exxon Mobile, General Electric, Gilead, Intel, Nasdaq, Nvidia, PepsiCo, Philips, Procter & Gamble, Swiss Helveita, Walt Disney, Wells Fargo, and Zimmer Biomet).

Clinical Trial

The clinical trial was registered as NCT03544125 under ClinicalTrials.gov. The trial was registered prospectively to this study.

Funding Statement

This project was supported by the OHSU Knight Cancer Institute NCI Cancer Center Support Grant P30CA069533. GBM: NCI grant U01CA217842, Komen SAC110052 and Breast Cancer Research Foundation BCRF□19-110. ML: Ovarian Cancer Research Alliance and Ruth and Steve Anderson, in honor of Shae Anderson Gerlinger. YHC: NCI grant U54CA209988 and U2CCA233280. RB: DOD PC190174 and PC141395, Veterans Administration Merit Award IBX002842A, NIH R01GM086688 and P30 CA69533, Prospect Creek Foundation. JWG: NIH/NCI U2C CA233280; NIH/NCI U54 CA209988; NIH U54 HG008100; NIH/NCI P30 CA69533; Brenden Colson; PDX Pharmaceuticals, LLC/NCI SRA-14-040 (R44, N43-CO-2013-00078); NIH U01 CA195469, Harvard University Subaward; Susan G. Komen Foundation SAC110012. ARG: R01 DK117459-01, 1 U2C-CA23380-01, The V Foundation for Cancer Research T2015-004. JG: U24-CA231877, U2C-CA233280. AC: U2C-CA233280. PTS: NIH U24CA210957, U01CA195469, P30CA069533, U01CA199315, U01CA232819, R01CA248383, R01, U01, DOD BC151431P1, Knight Cancer Institute.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was reviewed and approved by the OHSU Institutional Review Board.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

There is no external datasets or online supplementary material.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 29, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations
Marilyne Labrie, Allen Li, Allison Creason, Courtney Betts, Jamie Keck, Brett Johnson, Shamilene Sivagnanam, Christopher Boniface, Hongli Ma, Aurora Blucher, Young Hwan Chang, Koei Chin, Jacqueline Vuky, Alexander R. Guimaraes, Molly Downey, Jeong Youn Lim, Lina Gao, Kiara Siex, Swapnil Parmar, Annette Kolodzie, Paul T Spellman, Jeremy Goecks, Lisa M. Coussens, Christopher L. Corless, Raymond Bergan, Joe W. Gray, Gordon B. Mills, Zahi I. Mitri
medRxiv 2020.07.25.20146431; doi: https://doi.org/10.1101/2020.07.25.20146431
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations
Marilyne Labrie, Allen Li, Allison Creason, Courtney Betts, Jamie Keck, Brett Johnson, Shamilene Sivagnanam, Christopher Boniface, Hongli Ma, Aurora Blucher, Young Hwan Chang, Koei Chin, Jacqueline Vuky, Alexander R. Guimaraes, Molly Downey, Jeong Youn Lim, Lina Gao, Kiara Siex, Swapnil Parmar, Annette Kolodzie, Paul T Spellman, Jeremy Goecks, Lisa M. Coussens, Christopher L. Corless, Raymond Bergan, Joe W. Gray, Gordon B. Mills, Zahi I. Mitri
medRxiv 2020.07.25.20146431; doi: https://doi.org/10.1101/2020.07.25.20146431

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1946)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (699)
  • Epidemiology (11102)
  • Forensic Medicine (8)
  • Gastroenterology (624)
  • Genetic and Genomic Medicine (3168)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12720)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2986)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1552)
  • Ophthalmology (477)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2784)
  • Public and Global Health (5591)
  • Radiology and Imaging (1093)
  • Rehabilitation Medicine and Physical Therapy (634)
  • Respiratory Medicine (759)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)